Site Search
Professionals 25 results
Capabilities 5 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Industry
Experience 1 result
Experience
|January 18, 2022
ProKidney Business Combination with Social Capital Suvretta Holdings Corp. III
Winston & Strawn represented the Placement Agents, including Citigroup Global Markets, Inc.; Morgan Stanley; Evercore; and Jefferies LLC, in connection with the business combination between ProKidney LP, a leading clinical-stage cellular and gene therapeutics company focused on chronic kidney disease (CKD), and Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC), a special purpose acquisition company (SPAC), which will result in ProKidney becoming a publicly traded company. Upon closing, the transaction will accelerate ProKidney’s mission to change the lives of tens of millions of CKD patients through a first-of-its-kind disease-modifying cellular and gene therapy. The transaction values the combined company at a pro forma enterprise value of US$1.84B and is expected to provide up to US$750M in gross cash proceeds, including a fully committed PIPE of US$500M, and up to US$250M of cash held in the trust account of Social Capital Suvretta Holdings Corp. III. The PIPE is led by US$125M from Social Capital, with US$50M from ProKidney’s existing investors and participation from Investors. ProKidney is developing a technology to treat CKD by using the patient’s own cells to restore kidney function, according to its website. The company was started by a group of investors led by Pablo Legorreta, the founder and CEO of Royalty Pharma Plc. Proceeds from the transaction will fund the phase-three development of the company’s lead product candidate, accelerate manufacturing build-out, and ultimately prepare for a global commercial launch. The partnership between Palihapitiya and Suvretta Capital has so far resulted in four SPACs that have each raised US$250M. The SPACs are each targeting a different subsector within biotechnology: neurology, oncology, organs, and immunology.
Insights & News 39 results
Speaking Engagement
|October 29, 2024
Keerthika Subramanian Joins AI Governance Panel to Discuss Legal Challenges and Corporate Solutions
On October 29, 2024, capital markets partner Keerthika Subramanian participated in an AI Governance panel hosted by Carnegie Mellon University's Heinz School of Business as part of its Chief Data and Artificial Intelligence Officer Certificate Program. She was joined by Krishna Cheriath, Chief Data, Analytics, and AI Officer at Thermo Fisher Scientific's Clinical Research Group, and Matt DeVoe, VP and Chief Information Security Officer at Zoetis Inc.
In the Media
|August 14, 2024
|1 Min Read
Keerthika Subramanian Discusses U.S. IPO Market Activity with International Financing Review
Winston & Strawn partner Keerthika Subramanian was quoted in a recent International Financing Review article discussing the state of the U.S. IPO market for the remainder of 2024.The market has been stunted, but not entirely closed, following an increased selloff in stocks amid signs of a slowing economy that raised expectations the U.S. Federal Reserve may be forced to cut interest rates sharply, though major deals are not expected to come until 2025. Historically, August sees a decrease in U.S. IPO issuance, and 2024 will have an added complexity of the presidential election in November.
In the Media
|July 2, 2024
|1 Min Read
Keerthika Subramanian Discusses Midyear Outlook for Equity Capital Markets with Law360
Winston & Strawn partner Keerthika Subramanian was quoted in a Law360 article discussing the outlook for equity capital markets in the second half of the year. Capital markets activity moderately accelerated in the year’s first six months, buoyed by the highest level of initial public offerings in three years, signaling a busy second half for deal-makers.
Other Results 1 result
Location
Since 1995, Winston & Strawn’s Paris office has provided a wide range of transactional and litigation legal services to its clients. Our Paris attorneys are multilingual and multicultural. Many of them have gained professional experience abroad and are well-versed in managing the cultural and legal nuances often present in legal matters involving multiple jurisdictions. They are recognized by The Legal 500 EMEA, Leaders League, Best Lawyers® in France, and Palmares du Droit.